Total Payments
$384,750
2024 Payments
$9,235
Companies
41
Transactions
613
Medicare Patients
342
Medicare Billing
$44,245
Payment Breakdown by Category
Research$305,986 (79.5%)
Other$40,364 (10.5%)
Consulting$19,190 (5.0%)
Food & Beverage$10,291 (2.7%)
Travel$8,797 (2.3%)
Education$121.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $305,986 | 47 | 79.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,555 | 18 | 9.8% |
| Consulting Fee | $19,190 | 5 | 5.0% |
| Food and Beverage | $10,291 | 507 | 2.7% |
| Travel and Lodging | $8,797 | 31 | 2.3% |
| Debt forgiveness | $2,809 | 1 | 0.7% |
| Education | $121.76 | 4 | 0.0% |
Payments by Type
Research
$305,986
47 transactions
General
$78,764
566 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $302,716 | 37 | $0 (2018) |
| Corium, LLC | $35,320 | 59 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $9,963 | 26 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $9,301 | 18 | $0 (2024) |
| Shire North American Group Inc | $7,401 | 45 | $0 (2019) |
| IRONSHORE PHARMACEUTICALS INC. | $5,360 | 32 | $0 (2024) |
| Neuronetics, Inc. | $3,025 | 8 | $0 (2024) |
| Roche Products Limited | $1,780 | 3 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,772 | 7 | $0 (2020) |
| H. Lundbeck A S | $1,498 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,235 | 97 | Corium, LLC ($4,707) |
| 2023 | $25,917 | 132 | Corium, LLC ($14,607) |
| 2022 | $17,181 | 90 | Corium, LLC ($15,918) |
| 2021 | $10,170 | 70 | Supernus Pharmaceuticals, Inc. ($9,230) |
| 2020 | $1,991 | 19 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,772) |
| 2019 | $13,509 | 74 | Shire North American Group Inc ($5,826) |
| 2018 | $88,289 | 78 | Rhodes Pharmaceuticals L.P. ($85,897) |
| 2017 | $218,457 | 53 | Rhodes Pharmaceuticals L.P. ($216,819) |
All Payment Transactions
613 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $6.81 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ADHD | ||||||
| 12/09/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: ANTI-ANXIETY | ||||||
| 12/04/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $29.08 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/02/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.90 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: ANTI-ANXIETY | ||||||
| 11/15/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Education | In-kind items and services | $11.87 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/14/2024 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Debt forgiveness | Cash or cash equivalent | $2,808.76 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.82 | General |
| 11/03/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $22.00 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 10/31/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $33.24 | General |
| Category: Neuropsychiatry | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.28 | General |
| 10/23/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: SCHIZOPHRENIA | ||||||
| 10/22/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 10/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Neuroscience | ||||||
| 10/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: CNS | ||||||
| 10/07/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: ANTI-ANXIETY | ||||||
| 10/07/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RP-BP-EF003 | Rhodes Pharmaceuticals L.P. | $188,037 | 12 |
| RP-BP-EF004 | Rhodes Pharmaceuticals L.P. | $114,679 | 25 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,772 | 7 |
| Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD | H. Lundbeck A S | $1,498 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 78 | 173 | $21,650 | $10,754 |
| 2022 | 2 | 78 | 179 | $22,055 | $9,742 |
| 2021 | 2 | 85 | 190 | $24,370 | $12,090 |
| 2020 | 3 | 101 | 205 | $26,270 | $11,659 |
Total Patients
342
Total Services
747
Medicare Billing
$44,245
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 113 | $14,680 | $8,148 | 55.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 60 | $6,970 | $2,606 | 37.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 92 | $12,375 | $6,043 | 48.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 87 | $9,680 | $3,699 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 141 | $18,640 | $10,072 | 54.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 31 | 49 | $5,730 | $2,018 | 35.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 54 | 141 | $18,540 | $9,052 | 48.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 33 | 49 | $5,880 | $2,048 | 34.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 14 | 15 | $1,850 | $558.60 | 30.2% |
About Dr. Nelson Handal, M.D
Dr. Nelson Handal, M.D is a Child & Adolescent Psychiatry healthcare provider based in Dothan, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1154471548.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nelson Handal, M.D has received a total of $384,750 in payments from pharmaceutical and medical device companies, with $9,235 received in 2024. These payments were reported across 613 transactions from 41 companies. The most common payment nature is "" ($305,986).
As a Medicare-enrolled provider, Handal has provided services to 342 Medicare beneficiaries, totaling 747 services with total Medicare billing of $44,245. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Location Dothan, AL
- Active Since 01/10/2007
- Last Updated 04/26/2017
- Taxonomy Code 2084P0804X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1154471548
Products in Payments
- Aptensio XR (Drug) $302,716
- AZSTARYS (Drug) $20,432
- Azstarys (Drug) $14,888
- QUVIVIQ (Drug) $9,963
- QELBREE (Drug) $6,385
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $5,022
- NEUROSTAR TMS THERAPY SYSTEM (Device) $2,809
- REXULTI (Drug) $2,315
- Non-Covered Product (Drug) $1,860
- TRINTELLIX (Drug) $1,715
- VRAYLAR (Drug) $1,138
- SPRAVATO (Drug) $834.89
- Dyanavel XR (Drug) $564.41
- VYVANSE (Drug) $361.45
- CAPLYTA (Drug) $346.29
- JORNAY PM (Drug) $337.62
- FANAPT (Drug) $319.80
- Adzenys XR-ODT (Drug) $282.17
- LOREEV XR (Drug) $273.01
- INVEGA SUSTENNA (Drug) $256.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.